Mon. Apr 5th, 2021
EU in No Hurry to Get Sputnik V Into Market Over Competition Fears, Developer Says

“The EU is in no hurry to get Sputnik V as a full-fledged commercial product into its market, fearing its high consumer properties, thanks to which it could slightly push back the products that the European bureaucracy is promoting at home,” Gintsburg said.

Sputnik V, developed by the Gamaleya Epidemiology and Microbiology Centre, received an emergency use authorization in Russia back in August. The vaccine is 91.6 percent effective against symptomatic COVID-19 and is 100 percent effective against severe cases.

The shot is based on the well-studied human adenovirus vector platform and has been approved for use in almost 60 countries. The EU’s medicines regulator launched a review of the Russian vaccine in early March.

Facebook Comments

Leave a Reply

Translate »

This website uses cookies. By continuing to use this site, you accept our use of cookies.  Learn more

Share This